To investigate a possible relationship between the atherogenic properties of lipoprotein(a) (Lp(a)) and Chlamydia pneumoniae infections.
Introduction
Several studies have shown that high plasma levels of lipoprotein(a) are associated with coronary artery disease and acute myocardial infarction [1] [2] [3] [4] [5] . The possible pathogenic mechanisms are, however, not completely understood.
The known risk factors of coronary artery disease and acute myocardial infarction, e.g. hypertension, hypercholesterolaemia, diabetes mellitus and smoking, cannot entirely explain the aetiology of atherosclerotic diseases. In addition to traditional risk factors, infectious and immunological mechanisms have been suggested. The obligate intracellular bacterium Chlamydia pneumoniae is one of the pathogens that have been linked to atherosclerosis.
In this study, the contents of lipoprotein(a) and C. pneumoniae-specific IgG antibodies in circulating immune complexes were compared in patients suffering from acute myocardial infarction and in controls. This was done in order to explain and confirm previous findings indicating an association between C. pneumoniae, lipoprotein(a) and atherosclerosis.
Subjects and methods
The subjects in this study have previously been described [6] . All cases and controls participated in the Västerbotten Intervention Program [7] , a Northern Sweden community intervention programme, or in the WHO MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) project [8] that are running concurrently in Northern Sweden. Blood samples from 1985 onwards were donated to the NSMRB (Northern Sweden Medical Research Bank). Cases were defined on 30 September 1994. The inclusion criteria were fulfilled in 78 out of 243 reported acute myocardial infarction subjects in the Northern Sweden MONICA incidence registry. To fulfil the inclusion criteria, cases should not have had a cancer diagnosis according to the Swedish National Cancer Registry. Further, they should have participated in the Västerbotten Intervention Program or MONICA health surveys and donated a blood sample to the NSMRB prior to the acute myocardial infarction event. Individuals with a previous acute myocardial infarction were excluded.
Two matched controls for each case were randomly selected among participants in the health surveys who had not died or suffered acute myocardial infarction, stroke or cancer prior to or during the study period. Matching was performed for sex, age ( 2 years), date of health survey ( 1 year) and geographical region.
The final study group consisted of 78 patients (16 females and 62 males) with a mean age of 55·2 years and 156 controls with a mean age of 54·9 years. The mean time-span between examination day and onset of acute myocardial infarction was 18·4 months for the cases, and between sampling and inclusion 47·1 months for the controls. The mean time-span between sampling and onset of acute myocardial infarction did not differ significantly between cases with a positive or a negative C. pneumoniae antibody titre in serum or in circulating immune complexes (P>0·05).
The number of individuals with missing values was at most six per variable in the plasma and circulating immune complexes analyses and at most 17 in the other variables. Missing values were replaced in the conditional logistic regression analyses. The missing categorical variables were replaced by the value representing non-exposed and the continuous variables by the mean value for the control group. The multivariate analysis could not be performed separately in women since they were too few.
The blood sampling and the handling of drawn samples have been described elsewhere [6] . Samples were kept frozen at 80 C until analysed. All samples were thawed at the same time and analysed within a few days with the identities (whether cases or controls) masked.
Circulating immune complexes were precipitated using polyethylene glycol. The patient sample was added to an equal volume of 7% polyethylene glycol and incubated overnight at +4 C. After centrifugation at 7500 rpm for 15 min the pellet was washed twice with 3·5% polyethylene glycol borate [9] . The precipitates were then dissolved in phosphate buffered saline to the original volume.
The dissolved complexes and plasma were measured for the specific apolipoprotein(a) content with an inhouse ELISA technique. A catching polyclonal monospecific apolipoprotein(a) antibody was used. An established threshhold value for lipoprotein(a) in plasma is 300 mg . l 1 . This value was therefore chosen as a cut-off point.
The association between lipoprotein(a) in plasma and in circulating immune complexes was found to be linear. The correlation between lipoprotein(a) in plasma and in circulating immune complexes was evaluated by calculating the Pearson correlation coefficient (r=0·85; P<0·01) and the coefficient of determination (r 2 =0·72). Since lipoprotein(a) in plasma and in circulating immune complexes were asymmetrically distributed, the variables were logarithmically transformed before the Pearson correlation coefficient and the coefficient of determination were calculated. A lipoprotein(a) level in circulating immune complexes equal to 13 mg . l 1 was graphically estimated to be correlated to a lipoprotein(a) level in plasma of 300 mg . l 1 and was therefore chosen as the cut-off value. Lipoprotein(a) in circulating immune complexes and in plasma were analysed statistically as both continuous and categorical variables.
The contents of C. pneumoniae-specific IgG antibodies in the dissolved circulating immune complexes and in plasma were determined by microimmunofluorescence testing using TWAR strain Kajaani 6 as antigen [10] A C. pneumoniae IgG level d1/2 in circulating immune complexes was defined as positive [9] . An IgG titre in plasma of d1/32 was judged as positive and interpreted as a current or previous C. pneumoniae infection. The Medac rELISA (Medac, Germany), was used for determination of IgA antibodies against Chlamydialipopolysacharides in accordance with the instructions provided by the manufacturer. If the optical density was d0·7 the IgA level was considered positive.
The C. pneumoniae IgG measurements and the plasma precipitations were carried out at the National Public Health Institute in Oulu. The IgA ELISA analyses were performed at the Department of Virology, Umeå University.
Hypertension was defined as a systolic blood pressure >160 mmHg and/or a diastolic blood pressure >95 mmHg and/or individuals on antihypertensive medication. Smokers were defined as those reporting daily smoking. Ex-smokers and occasional smokers were classified as non-smokers.
Initially, the variables of primary interest, i.e. lipoprotein(a) and C. pneumoniae antibody titres in circulating immune complexes and in plasma, were analysed univariately. The variables used for adjustment were body mass index, C-reactive protein, diabetes mellitus, hypertension, total cholesterol, apolipoprotein A1, apolipoprotein B and smoking. These variables were chosen because of their well-known association with atherosclerosis and acute myocardial infarction. SPSS 7.5 for Windows was used for statistical analysis, continuity corrected chi-square tests, Fisher's exact test and independent samples t-tests. Odds ratios and confidence intervals were calculated using logistic regression analysis. These analyses were performed using the conditional maximum likelihood routine designed for matched analysis, available in the package EGRET.
The study was approved by the Research Ethics Committee at Umeå University and the data handling procedures by the National Computer Data Inspection Board.
Results
The proportion of individuals with a positive C. pneumoniae-specific IgG titre in circulating immune complexes did not differ significantly between cases and controls. Cases had a significantly higher mean lipoprotein(a) level in circulating immune complexes compared to controls, and the proportion of individuals with d13 mg . l 1 lipoprotein(a) in circulating immune complexes was significantly larger among cases (Table 1) . However, when the presence or absence of C. pneumoniae-specific IgG antibodies in circulating immune complexes were considered (while the proportion of individuals with circulating immune complexes containing d13 mg . l 1 lipoprotein(a) were compared) a significant difference between cases and controls was found only in individuals with a positive C. pneumoniae IgG level in their circulating immune complexes (P=0·013) ( Table 1) .
Similar results were found when men were analysed separately. No statistically significant differences could be found in women (Table 1) .
Results from the conditional logistic regression analysis show that individuals with circulating immune complexes containing d13 mg . l 1 lipoprotein(a) were 2·4 times more likely to suffer an acute myocardial infarction than individuals with less than 13 mg . l 1 lipoprotein(a) in circulating immune complexes (Table 2) . A positive C. pneumoniae IgG titre in circulating immune complexes was not found to be associated with an increased risk of acute myocardial infarction. Interaction was studied using the same categorizations. The risk of acute myocardial infarction was found to be 3·8 times higher in individuals with both a positive IgG titre in circulating immune complexes and d13 mg . l 1 lipoprotein(a) in circulating immune complexes ( Table  2 ). The interaction effect was calculated as: (3·8-1·6) (1·3 1)=1·9 indicating synergy [11, 12] . Similar figures were present in men, but not in women when analysed separately. The results only changed slightly after adjustment for hypertension, diabetes mellitus, body mass index, C-reactive protein, total cholesterol, apolipoprotein A1 and apolipoprotein B ( Table 2) . The results were somewhat altered when adjustment was also made for smoking ( Table 2 ). The odds ratio for the combined effect changed from 3·7 to 3·0.
In plasma, a significantly higher lipoprotein(a) level was found in patients compared to controls (Table 3) . A similar result was found when men and women were analysed separately. The difference in lipoprotein(a) level between cases and controls was, however, not statistically significant in women. A lipoprotein(a) level in plasma above 300·mg . l 1 was found to be associated with a two-fold higher risk of acute myocardial infarction. This increased risk remained after adjustment was performed (Table 4) . No difference was found between cases and controls in the proportion of individuals with a positive ELISA Chlamydia-lipopolysacharide IgA level or microimmunofluorescence (MIF) IgG antibody titre in plasma. Similar results were found when men and women were analysed separately ( Table 3) .
The prevalence rate of C. pneumoniae IgG seropositivity was significantly higher in smokers (67%) as compared to non-smokers (49%) (P=0·021). Daily smoking was reported in 39% of the cases and in 26% of the controls (P=0·078).
An association between C. pneumoniae-specific IgG antibodies in plasma and circulating immune complexes was observed; 82% of individuals positive for C. pneumoniae IgG antibodies in plasma were also positive for C. pneumoniae IgG antibodies in circulating immune complexes. Among individuals negative for C. pneumoniae IgG antibodies in plasma, 24% had a positive C. pneumoniae IgG antibody level in circulating immune complexes. Cases and controls did not differ in this aspect.
Discussion
A high lipoprotein(a) level has in many previous studies been shown to be an independent risk factor for the development of cardiovascular disease [1] [2] [3] [4] [5] . The results regarding lipoprotein(a) in our present study are in agreement with previous findings [6] . We found significantly higher lipoprotein(a) levels in patients with acute myocardial infarction compared to controls.
In addition to traditional risk factors, an infectious aetiology of atherosclerosis has been proposed. A number of different pathogens have been investigated. The first serologic evidence of an association between C. pneumoniae and coronary artery disease was provided by Saikku et al. in 1988 [13] . In a study by Dahlén et al., a positive C. pneumoniae IgG titre was found to be significantly more common in patients with early atherosclerosis than in controls [14] . We could not, however, confirm these results in the present study since no significant differences between patients and controls regarding C. pneumoniae-specific IgG and C. pneumoniae lipopolysacharides IgA titres were found.
The prevalence of C. pneumoniae-specific IgG antibodies increases with age. More than 50% of middleaged adults, with or without coronary artery disease and/or a history of acute myocardial infarction, have C. pneumoniae-specific antibodies [15] . In our study population, with a mean age of about 55 years, 53% of the cases and 55% of the controls had positive C. pneumoniae IgG antibody titres. To our knowledge, the controls in our study population have not had an acute myocardial infarction. They can, however, still have atherosclerotic changes in their coronary arteries which possibly could, Adjustment made for smoking, hypertension, diabetes, C-reactive protein, body mass index, total cholesterol, apolipoprotein A1 and apolipoprotein B.
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at least partly, be due to past or chronic C. pneumoniae infection. Serology has been shown to be an unsatisfactory marker of the C. pneumoniae-associated arterial disease status [16] . In fact, C. pneumoniae has to a greater extent been found in vessels from individuals with a low C. pneumoniae-specific IgG titre than in individuals with a high IgG titre [17] . Smoking is associated with the development of atherosclerotic disease. In this study, the proportion of smokers was larger among cases than controls, even though the difference was statistically non-significant. An association between smoking and C. pneumoniae titres has previously been described [18, 19] . In the present study, the prevalence of C. pneumoniae IgG seropositivity was significantly higher among smokers as compared to non-smokers. Smoking may increase the risk of being infected with C. pneumoniae and should probably be regarded as a confounder of the association between C. pneumoniae infections and the risk of coronary artery disease.
The prevalence of positive Chlamydialipopolysacharides IgA titres did not differ significantly between cases and controls. A serological test, the Medac rELISA, was used for Chlamydialipopolysacharide IgA analysis. This method has some advantages compared to the MIF test, as it is less time-consuming and more objective. However, the genus specificity of chlamydial lipopolysacharides can lead to cross-reactivity between the different chlamydial species- [20, 21] . Consequently, the Medac rELISA cannot differentiate between antibodies against different chlamydial species. The sensitivity and specificity of the Medac test for the diagnosis of C. pneumoniae have been shown to be low [22] . The present results, obtained using the Medac test, must therefore be regarded as less reliable than the results by MIF test.
The absence of differences between patients and controls regarding C. pneumoniae-specific IgG and Chlamydia-lipopolysacharide IgA antibody titres does not necessarily lead to the conclusion that C. pneumoniae is not involved in the atherosclerotic process, but rather that the chosen methods for detecting differences are not good enough. For example, it is perhaps not possible to distinguish between a past or an ongoing C. pneumoniae infection by serological methods. Our results are in agreement with an earlier study by Ridker et al. [19] where no association was found between C. pneumoniae IgG seropositivity and the risk of future myocardial infarction.
Circulating immune complexes may play a pathogenetic role in various heart diseases [23] [24] [25] . Patients with different types of heart diseases have been shown to have higher levels of IgG and IgM containing circulating immune complexes in their serum compared to controls [26] . Between 50% and 70% of patients suffering acute myocardial infarction have in previous studies been shown to carry circulating immune complexes [27, 28] . Serum from patients with coronary heart disease induces accumulation of lipids in cultured cells [29] . Removal of circulating immune complexes, IgG and IgM from the atherogenic sera results in a partial, or in some cases complete, elimination of the atherogenic properties in the sera. Cholesterol-containing immune complexes have been postulated to be responsible for the atherogenicity. Lipoproteins bound within the circulating immune complexes are probably the carriers of the cholesterol [29] . Significantly higher relative amounts of circulating immune complexes-derived C. pneumoniae-specific antibodies have been found in patients with coronary heart disease compared to controls [9] . In our study population, 61% of the cases compared to 53% of the controls were positive for C. pneumoniae-specific IgG antibodies in circulating immune complexes. This difference is not statistically significant and the previous findings could thus not be verified in the present study.
The pathogenic mechanisms linking high lipoprotein(a) levels to atherosclerotic disorders have still not been fully explained. One important discovery was the striking homology between structures in apolipoprotein(a) and in plasminogen [30] . This finding presented a structural basis for in vivo competition with plasminogen for binding to plasminogen receptors on endothelial cells and to fibrin which could damage the endothelial cells or inhibit fibrinolysis on the arterial wall, since lipoprotein(a) resists activation by the tissue plasminogen activator (t-PA).
In 1994, Dahlén proposed a hypothesis linking immunological mechanisms, high lipoprotein(a) levels, C. pneumoniae and atherosclerosis [31] . The serine protease domain in apolipoprotein(a) has structural resemblance with the trypsin unit of the non-pathogenic bacterium Streptomyces griseus [31, 32] . It was suggested that crossreactivity between antibodies against pathogenic bacterial epitopes and apolipoprotein(a) in lipoprotein(a) could occur if structural similarities exist [31, 33] . In a similar way C. pneumoniae-specific antibodies may form circulating immune complexes with apolipoprotein(a) in lipoprotein(a).
Certain HLA class II DR genotypes have been found to be significantly more common in male patients with early coronary artery disease than in controls, especially in patients with high lipoprotein(a) levels [14] . These results indicate that an immune response to lipoprotein(a) antigenic sites might occur, restricted to the HLA class II system. The high lipoprotein(a) level may be related to HLA class II DR genotypes. T-cells cannot be activated by an HLA-presented antigen alone. Therefore, secondary simultaneous co-stimulatory signals are needed. Further, the B 7 surface molecules expressed by antigen-presenting cells are strong co-stimulatory signal carriers. These molecules can also be expressed by macrophages separately from the cell which presents the HLA antigen complex. Macrophages express B 7 molecules when they are infected, C. pneumoniae is capable of multiplying in monocytes-macrophages [34] and has moreover been found in macrophages in atherosclerotic lesions [35] . Lipoprotein(a) is known to be taken up by macrophages [36] . If C. pneumoniae is present in macrophages in the arterial wall and epitopes from apolipoprotein(a) are presented at the same time, the T-cells may be activated resulting in T-cell proliferation and release of interferon-. This process would result in further activation of macrophages, induction of HLA class II antigens and the formation of circulating immune complexes containing apolipoprotein(a) immunoreactive epitopes [33] . The harmful effects of a high lipoprotein(a) level could be further aggravated by the presence of a chronic C. pneumoniae infection leading to the formation of circulating immune complexes, possibly causing faster progression of the atherosclerotic process. The results in this study are in support of these theories. In the present study, a significantly larger proportion of cases than controls were found to have circulating immune complexes containing a high amount of lipoprotein(a) and also C. pneumoniae-specific IgG antibodies. The presence of circulating immune complexes containing lipoprotein(a) and C. pneumoniaespecific IgG antibodies was associated with a 3·8 times increased risk of developing acute myocardial infarction. When controlled for other risk factors, such as hypertension, diabetes mellitus, C-reactive protein, body mass index, total cholesterol, apolipoprotein A1 and apolipoprotein B, the odds ratio was only slightly reduced to 3·7. However, when also adjusted for smoking the odds ratio was reduced to 3·0 indicating a confounding effect of smoking. The risk increase associated with a lipoprotein(a) level in plasma above 300 mg . l 1 was in this study 2·0. There seems to be a tendency towards synergism between high lipoprotein(a) levels in circulating immune complexes and C. pneumoniae IgG antibodies in circulating immune complexes judging by the fact that the relative excess risk due to interaction was found to be larger than zero [11, 12] . These findings indicate that a chronic C. pneumoniae infection might aggravate the proatherogenic effects of a high lipoprotein(a) level by the formation of circulating immune complexes containing C. pneumoniae-specific IgG antibodies.
